ProfileGDS5678 / 1428155_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 81% 82% 80% 83% 83% 81% 82% 82% 81% 82% 81% 82% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9084982
GSM967853U87-EV human glioblastoma xenograft - Control 25.8101481
GSM967854U87-EV human glioblastoma xenograft - Control 35.9027982
GSM967855U87-EV human glioblastoma xenograft - Control 45.8774980
GSM967856U87-EV human glioblastoma xenograft - Control 56.1663783
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.8868983
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6830681
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.8834782
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.8919282
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.897781
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9077882
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.8876481
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.8872582
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0388283